Structural Biochemistry/Bosulif

From Wikibooks, open books for an open world
< Structural Biochemistry
Jump to navigation Jump to search

Introduction[edit | edit source]

Chemical structure of bosutinib.

Bosulif (Bosutinib) is a new drug that is approved recently by the U.S. Food and Drug Administration (FDA) in order to treat people with Philadelphia chromosome- which is a genetic mutation when an enzyme called tyrosine kinase is produced by the bone marrow. This drugs is used to treat people with positive chronic myelogenous leukemia (CML). A positive CML is when a patient encounters chronic, accelerated CML. Bosulif is an Abl and Src kinase inhibitor. It contains mainly bosutinib which is shown in the picture. Because it is a new drug, so it is recommended to be used only when patients are not tolerated with other treatments. With this approval, we have seen an effective improvement in this treatment.

Usage and Side Effects[edit | edit source]

Bosulif cannot be used for patients who are allergic to bosutinib or any ingredient that belongs to this drug. It is produced as a tablet so you can easily use this with food. Avoid to use grapefruit or grape juice with this drug since Bosulif can be absorbed in the presence of stomach acid, that means the amount of Bosulif will be increased. You have to consult your doctor for doses and only take only the same amount that is prescribed. This drug also has some serious side effects if it is not used properly.

  • Stomach problem, diarrhea, vomit, headache, cough, fever.
  • Low blood cell counts, liver problems
  • Shortness of breath, chest pain, weight gain.

Reference[edit | edit source]